MedTrace Logo

A Study of ANAVEX3-71 in Adults With Schizophrenia

NCT06245213 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2025-05-04

No results posted yet for this study

Summary

A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.

Conditions

Interventions

DRUG

ANAVEX3-71 oral capsules

ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.

DRUG

Placebo oral capsules

The placebo comparator for the study.

Sponsors & Collaborators

  • COGNISION

    collaborator UNKNOWN

  • Cognitive Research Corporation

    collaborator INDUSTRY

  • Hassman Research Institute

    collaborator UNKNOWN

  • Anavex Life Sciences Corp.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2025-06-30
Completion
2025-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06245213 on ClinicalTrials.gov